Login
Nature Biotechnology 25, 363 (2007) doi:10.1038/nbt0407-363
In view of concerns about safety, could Amgen's aggressive promotion of erythropoietin (EPO) have jeopardized its billion-dollar franchise?
ADVERTISEMENT
Top